Advertisement


Lourdes Gil Deza on Caring for Transgender Patients With Cancer

ASCO20 Virtual Scientific Program

Advertisement

Professor Lourdes Gil Deza, of the Instituto Oncológico Henry Moore, Buenos Aires, discusses her findings on the shortcomings of medical training when it comes to treating transgender patients, and the need to deepen clinical and communication skills to assist this population (Abstract 11002).



Related Videos

Gastrointestinal Cancer

Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract 11503).

Multiple Myeloma

Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed or refractory multiple myeloma, with an overall response rate of 48%. The study is ongoing to further optimize dose and schedule (Abstract 8500).

Sarcoma

Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment

Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).

Skin Cancer
Immunotherapy

Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade

Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1 antibodies; and ipilimumab alone or in combination with anti–PD-1 therapy for metastatic disease resistant to PD-1 monotherapy (Abstracts 10003, 10004, and 10005).

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program

Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.

Advertisement

Advertisement




Advertisement